IN2014DN06966A - - Google Patents

Info

Publication number
IN2014DN06966A
IN2014DN06966A IN6966DEN2014A IN2014DN06966A IN 2014DN06966 A IN2014DN06966 A IN 2014DN06966A IN 6966DEN2014 A IN6966DEN2014 A IN 6966DEN2014A IN 2014DN06966 A IN2014DN06966 A IN 2014DN06966A
Authority
IN
India
Prior art keywords
relates
pregabalin
preparation
pharmaceutically acceptable
same
Prior art date
Application number
Other languages
English (en)
Inventor
Varinder Kumar
Shavej Ahmad
Romi Barat Singh
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48014113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN06966(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN6966DEN2014 priority Critical patent/IN2014DN06966A/en
Publication of IN2014DN06966A publication Critical patent/IN2014DN06966A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
IN6966DEN2014 2012-01-30 2013-01-29 IN2014DN06966A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN6966DEN2014 IN2014DN06966A (es) 2012-01-30 2013-01-29

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN252DE2012 2012-01-30
IN250DE2012 2012-01-30
IN6966DEN2014 IN2014DN06966A (es) 2012-01-30 2013-01-29
PCT/IB2013/050764 WO2013114283A1 (en) 2012-01-30 2013-01-29 Gastroretentive tablets

Publications (1)

Publication Number Publication Date
IN2014DN06966A true IN2014DN06966A (es) 2015-04-10

Family

ID=48014113

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6966DEN2014 IN2014DN06966A (es) 2012-01-30 2013-01-29

Country Status (7)

Country Link
US (1) US9393205B2 (es)
EP (1) EP2809304A1 (es)
AU (1) AU2013213769A1 (es)
CA (1) CA2863376A1 (es)
IN (1) IN2014DN06966A (es)
WO (1) WO2013114283A1 (es)
ZA (1) ZA201405581B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013114281A1 (en) * 2012-01-30 2013-08-08 Ranbaxy Laboratories Limited Pregabalin gr tablets
US20160338949A1 (en) * 2014-01-28 2016-11-24 Sun Pharmaceutical Industries Limited Stabilized gastroretentive tablets of pregabalin
WO2015174684A1 (ko) * 2014-05-14 2015-11-19 동아에스티 주식회사 방출제어된 위체류 서방성 제제
EP3498260A1 (en) 2017-12-12 2019-06-19 Pro.Med.CS Praha A.S. Oral gastroretentive sustained-release pharmaceutical formulation
TW202002958A (zh) * 2018-03-22 2020-01-16 日商日東電工股份有限公司 含普瑞巴林(pregabalin)之組成物的製造方法及含普瑞巴林之組成物
WO2019238068A1 (zh) 2018-06-13 2019-12-19 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CN111053749B (zh) * 2018-10-16 2022-07-15 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
CN110974798A (zh) * 2019-12-19 2020-04-10 江苏优仿医药科技有限公司 药物组合物、缓释片剂及其制备方法
CN114796142A (zh) * 2022-04-08 2022-07-29 黄山学院 萘普生胃漂浮片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ-氨基丁酸及其衍生物
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
EP2217217B1 (en) 2007-11-23 2018-05-30 Lupin Limited Controlled release pharmaceutical compositions of pregabalin
EP2440190A1 (en) 2009-06-12 2012-04-18 Micro Labs Limited Novel pharmaceutical compositions containing pregabalin
WO2011151708A1 (en) 2010-06-01 2011-12-08 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs

Also Published As

Publication number Publication date
US9393205B2 (en) 2016-07-19
US20150025146A1 (en) 2015-01-22
EP2809304A1 (en) 2014-12-10
ZA201405581B (en) 2015-06-24
CA2863376A1 (en) 2013-08-08
WO2013114283A1 (en) 2013-08-08
AU2013213769A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
IN2014DN06966A (es)
EP4249055A3 (en) Tofacitinib oral sustained release dosage forms
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2014004862A (es) Formulaciones de polimero acrilico.
EP3102188A4 (en) Novel disintegration systems for pharmaceutical dosage forms
IN2015DN03984A (es)
PH12016501841A1 (en) Immunosuppressant formulation
PH12014502856A1 (en) Solid pharmaceutical preparation containing levothyroxine
IN2014DN06965A (es)
IN2013MU01985A (es)
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
MX2017015322A (es) Composicion farmaceutica oral de isotretinoin.
IN2013MU01111A (es)
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
PH12014502325A1 (en) Sustained release tablet containing levodropropizine and method for preparing same
IN2012DE00826A (es)
WO2014122671A3 (en) Solid oral compositions of saxagliptin
IN2013MU03422A (es)
IN2013CH04314A (es)
MX2014010038A (es) Tabletas dispersables con sabor enmascarado.
WO2014013090A3 (en) Formulation comprising amorphous fingolimod
IN2013MU03428A (es)
IN2013MU02631A (es)
IN2014MU00781A (es)